Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland.
University of Zurich, Zurich, Switzerland.
Eur Arch Otorhinolaryngol. 2020 Apr;277(4):1039-1044. doi: 10.1007/s00405-020-05819-w. Epub 2020 Jan 27.
To determine the minimal clinically important difference (MCID) of the Zurich Chronic Middle Ear Inventory (ZCMEI-21), a questionnaire assessing health-related quality of life (HRQoL) in chronic otitis media (COM).
In this longitudinal study, 103 patients completed the ZCMEI-21 before and after surgery for chronic otitis media. An anchor-based method including a global rating of change (GRC) was used to assess the MCID of the ZCMEI-21.
A total of 103 patients were included. The mean preoperative and postoperative ZCMEI-21 scores were 28.6 (SD 13.6), and 21.8 (SD 12.8), respectively. The mean change was 6.8 (SD 0.8; p < 0.0001). A significant correlation between the ZCMEI-21 scores and the GRC was found (r = - 0.5; p < 0.001). Using the anchor-based method, the MCID of the ZCMEI-21 was estimated at 5.3 (SD 12.0).
Knowledge of values indicating a clinically relevant change in patient-reported outcome measures is important when interpreting effects of different treatment modalities. This is the first study assessing the MCID of a questionnaire measuring HRQoL in COM, i.e. the ZCMEI-21. We recommend a MCID of 5 in COM patients undergoing surgical treatment. This information substantially increases the usefulness of the ZCMEI-21 as an outcome measure in COM as changes can be assessed with regard to their clinical meaningfulness.
确定评估慢性中耳炎(COM)患者健康相关生活质量(HRQoL)的 Zurich 慢性中耳量表(ZCMEI-21)的最小临床重要差异(MCID)。
在这项纵向研究中,103 例慢性中耳炎患者在手术前后完成了 ZCMEI-21 量表。采用基于锚定的方法,包括变化整体评估(GRC),评估 ZCMEI-21 的 MCID。
共纳入 103 例患者。术前和术后 ZCMEI-21 评分的均值分别为 28.6(SD 13.6)和 21.8(SD 12.8)。平均变化为 6.8(SD 0.8;p<0.0001)。ZCMEI-21 评分与 GRC 之间存在显著相关性(r=-0.5;p<0.001)。基于锚定的方法,ZCMEI-21 的 MCID 估计为 5.3(SD 12.0)。
了解患者报告结局测量值中表明临床相关变化的数值对于解释不同治疗方式的效果非常重要。这是第一项评估 COM 患者 HRQoL 测量问卷(即 ZCMEI-21)MCID 的研究。我们建议在接受手术治疗的 COM 患者中,MCID 为 5。这一信息极大地提高了 ZCMEI-21 在 COM 中的实用性,因为可以根据其临床意义评估变化。